1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €11.39 (+607.45%). The median is €13.81 (+757.76%).
| Buy |
13 |
| Hold |
5 |
| Sell |
2 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 29.29M | 8.97% |
| Gross profit | 28.34M | 9.41% |
| Net profit | -58.73M | 85.81% |
| EBITDA | -47.21M | 114.80% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €37.95M |
Number of shares | 22.66M |
52-week high/low | €9.49 - €1.54 |
| Dividends | No |
Beta | 0.95 |
P/E ratio | -0.09 |
PEG ratio | 0.00 |
P/B ratio | -0.17 |
P/S ratio | 0.30 |
Company profile
| Name | Karyopharm Therapeutics |
| CEO | Richard A. Paulson |
| Employees | 228 |
Discover assets
Shareholders of Karyopharm Therapeutics also invest in the following assets
